<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860635</url>
  </required_header>
  <id_info>
    <org_study_id>100-CIP03-P</org_study_id>
    <nct_id>NCT04860635</nct_id>
  </id_info>
  <brief_title>Safety of F14 Following Total Knee Replacement</brief_title>
  <official_title>An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthritis Innovation Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arthritis Innovation Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and&#xD;
      multimodal analgesia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study superseded by alternative Phase 3 trial&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>From Day 0 to 12 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>NRS pain intensity</measure>
    <time_frame>From Day 1 to 3 months</time_frame>
    <description>Numerical rating scale (NRS); 11-point scale ranges from '0' representing &quot;no pain&quot; to '10' representing &quot;worst imaginable pain&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of need for walking aids</measure>
    <time_frame>From Day 1 to 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects using concomitant analgesics at any timepoint</measure>
    <time_frame>From Day 1 to 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Celecoxib concentration in plasma</measure>
    <time_frame>At specified timepoints up to 3 months</time_frame>
    <description>PK sub-study in 15 participants</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>F14 (sustained release celecoxib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular F14 administration immediately following TKR surgery, and concurrent with multimodal standard of care analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F14 (sustained release celecoxib)</intervention_name>
    <description>Celecoxib in BEPO® drug delivery system</description>
    <arm_group_label>F14 (sustained release celecoxib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and/or females indicated for primary, unilateral TKR&#xD;
&#xD;
          2. Between 45-80 years of age&#xD;
&#xD;
          3. Capable of giving signed informed consent&#xD;
&#xD;
          4. Body Mass Index (BMI) ≤ 40 kg/m2&#xD;
&#xD;
          5. Medically stable as determined by the Investigator, based on physical examination,&#xD;
             clinical laboratory tests, and 12-lead ECG findings, as well as medical history from&#xD;
             subject and pre-study source documents from other care providers&#xD;
&#xD;
          6. Absence of fixed flexion deformity exceeding 15deg&#xD;
&#xD;
          7. Absence of varus or valgus deformity exceeding 15deg&#xD;
&#xD;
          8. Minimum pre-operative flexion arc of 100deg&#xD;
&#xD;
          9. American Society of Anesthesiologists Physical Status Classification System (ASA-PSC)&#xD;
             score ≤ 3&#xD;
&#xD;
         10. Females of childbearing potential with a negative serum pregnancy test at screening or&#xD;
             males with a partner that is of childbearing potential, who agree to employ adequate&#xD;
             birth control measures for the full duration of the study&#xD;
&#xD;
         11. Has undergone successful total knee replacement surgery, which in the opinion of the&#xD;
             Investigator, will not affect the subject's study follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy or hypersensitivity to active ingredient celecoxib, OR known allergy or&#xD;
             hypersensitivity to sulfonamide antibiotics or sulfa containing drugs when an allergy&#xD;
             to celecoxib is unknown&#xD;
&#xD;
          2. Unwilling or unable to discontinue use of nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs) within 7 days of scheduled surgery, or medical marijuana or cannabidiol (CBD)&#xD;
             within 10 days&#xD;
&#xD;
          3. Total or partial knee arthroplasty in the contralateral knee &lt; 6 months prior to study&#xD;
             surgery&#xD;
&#xD;
          4. Participation or scheduled participation in another clinical study involving an&#xD;
             investigational drug or device within 30 days before screening or during study&#xD;
             follow-up&#xD;
&#xD;
          5. Active or past infection in the index knee&#xD;
&#xD;
          6. Documented osteonecrosis of the index knee within previous 12 months&#xD;
&#xD;
          7. Other planned major surgery within 12 months of study surgery&#xD;
&#xD;
          8. Had a malignancy in the last year, except for non-metastatic basal cell or squamous&#xD;
             cell carcinoma of the skin or localized carcinoma in situ of the cervix&#xD;
&#xD;
          9. Diagnosis of skin disorders including psoriasis, vascular insufficiency ulcers, and&#xD;
             chronic venous stasis&#xD;
&#xD;
         10. History of coronary or vascular stent placed within 3 months&#xD;
&#xD;
         11. Suspected opioid abuse in the last 12 months with a score exceeding 5 on the DAST-10&#xD;
             questionnaire, and/or taking opioids on most days in the past three months, and&#xD;
             currently taking &gt;120 mg morphine equivalent dose (MED) at least 5 days per week in&#xD;
             the month prior to screening&#xD;
&#xD;
         12. Current medical diagnosis or subject-reported seizure disorder&#xD;
&#xD;
         13. Current peripheral neuropathy&#xD;
&#xD;
         14. History of complex regional pain syndrome (CRPS)&#xD;
&#xD;
         15. Diagnosis of clinically significant liver hepatic and/or renal abnormalities within&#xD;
             previous 2 years&#xD;
&#xD;
         16. Diagnosis of diabetes with HbA1c ≥7%&#xD;
&#xD;
         17. Current inflammatory arthritides (e.g., rheumatoid arthritis, lupus erythematosus,&#xD;
             ankylosing spondylitis, psoriatic arthritis), or traumatic bone injuries within 12&#xD;
             months before scheduled surgery, except for clinically stable/non-active gout that&#xD;
             does not affect the knee and does not interfere with walking&#xD;
&#xD;
         18. Treatment with immunosuppressants, antipsychotics, anticholinergics, or&#xD;
             anticonvulsants within 1 month of intervention (antipsychotic stable dosage&#xD;
             established for &gt;30 days will be allowed)&#xD;
&#xD;
         19. Current or historical evidence of any clinically significant disease or condition,&#xD;
             especially cardiovascular, pulmonary, or neurological&#xD;
&#xD;
         20. Participation in active or pending personal injury or workers' compensation litigation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Foran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Panorama Orthopedics &amp; Spine Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Panorama Orthopedics &amp; Spine Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total knee arthroplasty</keyword>
  <keyword>postoperative pain</keyword>
  <keyword>NSAID</keyword>
  <keyword>multimodal analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

